Qiao, Guilin
Kone, Lyonell B.
Phillips, Evan H.
Lee, Steve Seung-Young
Brown, Grace E.
Khetani, Salman R.
Thakur, Archana
Lum, Lawrence G.
Prabhakar, Bellur S. http://orcid.org/0000-0001-9815-9850
Maker, Ajay V. http://orcid.org/0000-0002-8234-2762
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA238435, K08CA190855, R00EB022636, R01CA140314, R01CA092344, P30CA044579)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Veterans Affairs (I01 BX004697)
U.S. Department of Health & Human Services | National Institutes of Health (R01 DK115747, R01CA140314)
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 6 March 2021
Revised: 7 January 2022
Accepted: 24 January 2022
First Online: 17 February 2022
Competing interests
: LGL is co-founder of Transtarget, Inc. and serves on the Scientific Advisory Board of Rapa Therapeutics.
: All authors consent to publication without conflict or reservation.